Tag Cloud

What is a tag cloud?

Current tags: Clear current tags
View full tag cloud
Advertisement
Q

In patients who present which their first episode of pulmonary embolism or proximal DVT or below knee DVT, with no known risk factors for thromboembolism, how long should warfarin therapy be continued for?

Associated tags: anticoagulation, Cardiovascular disease, DVT, treatment duration, warfarin

Question DetailsView Comments (0)
A

ANSWER

provided by Trip / NLH
Search
Moderate
Appraisal
Moderate
Confidence
Moderate

Answer Rating key

search strong
appraisal weak
confidence moderate

Question answered:23/04/08

The CKS guideline on DVT [1] states:

 

“Anticoagulation

 

Warfarin is the most commonly used anticoagulant for long-term therapy following a venous thromboembolic event.

 

The usual treatment strategy is to aim for an international normalization ratio (INR) of 2.5 and to keep it within 2.0–3.0.

 

The duration of treatment is usually 3 to 6 months, but may be shorter or longer, depending on the risk of recurrence.”

 

It later reports:

 

“The standard duration and intensity of anticoagulant treatment may vary according to the clinical features balancing the benefits of treatment against the risks of treatment and the risk of recurrence without treatment. Minimum recommended durations are shown in Table 1.

 

There is some debate about the benefits of anticoagulation for people who have had a first distal DVT. The British Committee for Standards in Haematology recommends (grade A) that they be given at least 6 weeks' therapy [Baglin et al, 2005]. However, an editorial in Thrombus questions the evidence that there are benefits in terms of both (i) preventing the thrombus extending and embolizing; and (ii) preventing the development of post-thrombotic syndrome [Rose, 2006].

 

Anticoagulants may need to be continued beyond the planned treatment period if there are ongoing risk factors for venous thromboembolism, for example, if the person has:
 - Inherited coagulation defects (e.g. factor V Leiden)
 - Acquired coagulation defects (e.g. antiphospholipid syndrome)
 - Malignancy
 - Chronic infection
 - Inflammatory bowel disease
 - Nephrotic syndrome
 - Thromboembolic pulmonary hypertension”

 

 

Reference

1) http://www.cks.library.nhs.uk/deep_vein_thrombosis/view_whole_guidance


DISCLAIMER: TRIPanswers is a collection of clinical questions and answers.  Each provider will have their own methodology in answering questions and these are likely not to be as rigorous as systematic review.  If you have any doubt as to the implications of this contact the Q&A Service Provider for further information. This document is presented for information purposes only. This document cannot and should not be used as a basis of diagnosis or choice of treatment, and is in no way intended to replace professional medical care or attention by a qualified practitioner. TRIPanswers and TRIP Database Ltd are not responsible or liable for, directly or indirectly, ANY form of damage whatsoever resulting from the use/misuse of information contained in or implied by this document.  Also, ensure you have read the terms and conditions for using the site.

Need to search for more evidence?

Help us improve this answer

Leave comments or suggestions below

Disclaimer:

TRIP will review each comment and will only publish those we feel will enhance a particular answer.  As a result of the review process there will be a delay between submission and publication of accepted comments.